Alimera Sciences Inc Stock Ownership - Who owns Alimera Sciences?

Insider buying vs selling

Have Alimera Sciences Inc insiders been buying or selling?
Adam MorganDirector2023-05-171,401,901$1.70
Palo Alto Investors LP10% Owner2023-03-24200,919$1.56
Philip AshmanChief Operating Officer SVP2023-02-032,889$2.81
Richard S. Eiswirth Jr.President and CEO2022-10-31500$4.44
David HollandChief Marketing Officer SVP2022-10-31500$4.44
John Philip JonesChief Financial Officer2022-10-31372$4.44

1 of 1

ALIM insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ALIM insiders and whales buy or sell their stock.

ALIM Shareholders

What type of owners hold Alimera Sciences Inc stock?
Armistice Capital LLC186.80%13,832,000$35.69MInsider
Palo Alto Healthcare Master Fund LP89.59%6,634,295$17.12MInsider
Venrock Associates Iv L P83.86%6,209,433$16.02MInsider
James E. Flynn79.38%5,878,015$15.17MInsider
Mark J. 1. Brooks65.67%4,863,094$12.55MInsider
Brian H. Dovey56.58%4,189,427$10.81MInsider
Nicole Vitullo56.58%4,189,427$10.81MInsider
James C. Blair56.58%4,189,427$10.81MInsider
Kathleen K. Schoemaker56.58%4,189,427$10.81MInsider
Jesse I. Treu56.58%4,189,427$10.81MInsider

1 of 3

ALIM vs Pharmaceutical Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ALIM2.27%97.73%Net BuyingNet Buying
CYTH1.60%98.40%Net BuyingNet Buying
DERM9.34%15.68%Net SellingNet Selling
MDVL35.67%64.33%Net BuyingNet Selling
ZYNE11.94%7.87%Net Selling

Alimera Sciences Stock Ownership FAQ

Who owns Alimera Sciences?

Alimera Sciences (NASDAQ: ALIM) is owned by 27.73% institutional shareholders, 1,191.61% Alimera Sciences insiders, and 0.00% retail investors. Armistice Capital LLC is the largest individual Alimera Sciences shareholder, owning 13.83M shares representing 186.80% of the company. Armistice Capital LLC's Alimera Sciences shares are currently valued at $36.52M.

If you're new to stock investing, here's how to buy Alimera Sciences stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.